Patent classifications
G01N2400/38
DNA-GLYCAN CONJUGATES AND METHODS OF USE
Provided herein are DNA-glycan conjugates that include a glycan and a covalently attached polynucleotide. The polynucleotide includes a plurality of modules. Each module includes a nucleotide string, and the plurality of modules includes a monomer module that corresponds to each carbohydrate monomer present in the DNA-glycan conjugate, and a linkage module that corresponds to each glycosidic linkage present between each carbohydrate monomer in the DNA-glycan conjugate. The nucleotide sequence of the plurality of modules corresponds to the glycan structure. Also provided herein are methods for making and using the DNA-glycan conjugates. Further provided is a computer-implemented method for translating data from a nucleotide sequence to a glycan structure, a system for converting data from a glycan structure to a nucleotide sequence, and a system for translating data from a nucleotide sequence to a glycan structure.
DNA-glycan conjugates and methods of use
Provided herein are DNA-glycan conjugates that include a glycan and a covalently attached polynucleotide. The polynucleotide includes a plurality of modules. Each module includes a nucleotide string, and the plurality of modules includes a monomer module that corresponds to each carbohydrate monomer present in the DNA-glycan conjugate, and a linkage module that corresponds to each glycosidic linkage present between each carbohydrate monomer in the DNA-glycan conjugate. The nucleotide sequence of the plurality of modules corresponds to the glycan structure. Also provided herein are methods for making and using the DNA-glycan conjugates. Further provided is a computer-implemented method for translating data from a nucleotide sequence to a glycan structure, a system for converting data from a glycan structure to a nucleotide sequence, and a system for translating data from a nucleotide sequence to a glycan structure.
GLYCAN-BASED DRUGS, THERAPIES AND BIOMARKERS
The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed.
GLYCAN ARRAYS FOR HIGH THROUGHPUT SCREENING OF VIRUSES
Glycan arrays that can detect and distinguish between various sub-types and strains of influenza virus are provided. Methods for using the glycan arrays with assays using nanoparticle amplification technique are disclosed. Sandwich assays using gold nanoparticles conjugated to phage particles comprising influenza virus-specific antibodies for detecting multiple serotypes using a single reaction are provided. Plurality of glycans directed to specific target HA of influenza virus comprises the array. Detector molecules comprising noble metals conjugated to (a) phage display particles expressing antibodies against hemagglutinin and (b) neuraminidase binding agents are disclosed.
Synthetic Oligosaccharide Subunits Of The PSL Exopolysaccharide Of Pseudomonas Aeruginosa And Uses Thereof
This disclosure relates to synthetic oligosaccharide subunits of the Pseudomonas exosaccharide Psi and uses thereof, e.g., for epitope mapping of anti-Psl antibodies, for identification of anti-Psl antibodies, and for use as vaccines. In one aspect a synthetic oligosaccharide subunit of a Pseudomonas aeruginosa Psl oligosaccharide is provided, comprising the trisaccharide of formula I.
GLYCAN ANALYSIS METHOD, GLYCAN ANALYSIS SYSTEM, PROGRAM FOR GLYCAN ANALYSIS, AND KIT FOR GLYCAN ANALYSIS
A sample, which is a mixture of glycans, is fluorescently labeled (S2). The sample is subsequently separated by microchip electrophoresis under a buffer solution with no lectin added as well as under multiple kinds of buffer solutions with different lectins respectively added, and the separated components are fluorescently detected (S3). A high-concentration gel which can produce a molecular-sieving effect is used as the buffer solution. Multiple electropherograms are created from the detection results (S4). A glycan having a lectin specifically attached is delayed during its migration in the buffer solution, so that a peak corresponding to this glycan will effectively disappear. Accordingly, based on the kinds of lectins and the presence/absence of a peak on each of the electropherograms, the structure of each glycan in the sample is estimated and the glycan is identified (S5).
Diagnostic method for gastric cancer
This invention relates to a method for gastric cancer diagnosis through the detection of glycan changes, and to a kit for gastric cancer diagnosis. More specifically, based on the fact that in gastric cancer patient-derived haptoglobin, there are changes in N-linked glycosylation of haptoglobin, which are detected through lectin and mass spectrometery, that is, an increase in fucosylation, increases or significant changes in specific glycan structures depending on the classification of antennary structures, or a remarkable decrease in a high mannose structure of the N-glycan as compared to normal persons, N-glycan structures identified using the changes in N-linked glycosylation of haptoglobin may be usefully used as a diagnosis marker in a method for gastric cancer diagnosis using lectin or mass spectrometry, and a kit for gastric cancer diagnosis.
Glycan Sample Preparation
The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol that can enable full automation and reduced sample preparation time relative to current methods of glycoanalysis. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method without requiring time-consuming sample preparation steps such as centrifugation or vacuum-centrifugation.
Glycan arrays for high throughput screening of viruses
Glycan arrays that can detect and distinguish between various sub-types and strains of influenza virus are provided. Methods for using the glycan arrays with assays using nanoparticle amplification technique are disclosed. Sandwich assays using gold nanoparticles conjugated to phage particles comprising influenza virus-specific antibodies for detecting multiple serotypes using a single reaction are provided. Plurality of glycans directed to specific target HA of influenza virus comprises the array. Detector molecules comprising noble metals conjugated to (a) phage display particles expressing antibodies against hemagglutinin and (b) neuraminidase binding agents are disclosed.
SULFUR-SUBSTITUTED SUGAR TO STABILIZE OLIGOSACCHARIDE
Glycosylated peptides and oligonucleotides of the invention contain oligosaccharides that include three or more saccharide moieties, wherein two saccharide moieties at a non-reducing terminal end of the oligosaccharide are coupled together with a thio-ether bond, and one of the saccharide moieties at a reducing end of the oligosaccharide is coupled to a reactive moiety. Also disclosed are immunogenic conjugates that include a glycopeptide or oligonucleotide bound to an immunogenic carrier molecule, as well as pharmaceutical compositions containing the same.